Galecto drug shows cancer treatment potential in Phase II trial
Biotech company Galecto has shown positive results from a Phase IIa trial with 18 patients with the blood cancer disease myelofibrosis who received treatment with GB2064.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Low share price may knock Galecto off the stock exchange
For subscribers